Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,559.77 43.50 0.30%
TOPIX 1,174.33 0.96 0.08%
HANG SENG 22,760.24 64.23 0.28%

Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research



 Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New
   Testing Procedures, and Partnerships - Research Report on Gilead, Health
               Management, IDEXX, ISIS, and Trius Therapeutics

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, June 18, 2013

NEW YORK, June 18, 2013 /PRNewswire/ --

Today, Wall Street Reports announced new research reports highlighting Gilead
Sciences, Inc. (NASDAQ: GILD), Health Management Associates Inc. (NYSE: HMA),
IDEXX Laboratories, Inc. (NASDAQ: IDXX), ISIS Pharmaceuticals Inc. (NASDAQ:
ISIS), and Trius Therapeutics Inc. (NASDAQ: TSRX). Today's readers may access
these reports free of charge - including full price targets, industry analysis
and analyst ratings - via the links below.

Gilead Sciences, Inc. Research Report

On June 7, 2013, Gilead Sciences Inc. (Gilead) announced that the US Food and
Drug Administration (FDA) has granted priority review to the New Drug
Application (NDA) for sofosbuvir, a once-daily oral nucleotide analogue
inhibitor for the treatment of chronic hepatitis C (HCV) infection. Priority
review status is granted to drug candidates that may offer major advances in
treatment over existing options. According to Gilead, the data submitted in
the NDA support the use of sofosbuvir and ribavirin (RBV) as an all-oral
therapy for patients with genotype 2 and 3 HCV infection, and of sofosbuvir in
combination with RBV and pegylated interferon (peg-IFN) for treatment-naïve
patients with genotype 1,4, 5, and 6 HCV infection. The Company filed the NDA
for sofosbuvir on April 8, 2013, and FDA has set a target review date under
the Prescription Drug User Fee Act (PDUFA) of December 8, 2013. The Full
Research Report on Gilead Sciences, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.wsreports.com/r/full_research_report/9696_GILD]

--

Health Management Associates Inc. Research Report

On June 11, 2013, Health Management Associates Inc. (Health Management)
announced that it has executed a letter of intent under which it would enter
into a long-term lease with Munroe Regional Medical Center (Munroe Regional)
and bring it into Health Management's clinical affiliation with the University
of Florida Health Shands Hospital. The letter of intent is the first step of a
due diligence process between Munroe Regional, Health Management, and UF
Health Shands Hospital toward a definitive agreement. Alan Levine, Senior Vice
President and Florida Group President for Health Management, said, "By
combining the talents of Munroe Regional, the resources of Health Management
and the academic strength of UF Health Shands Hospital, the partnership will
provide the region the best opportunity to strengthen and improve the health
of the community for years to come." The three parties involved expect to
execute the definitive agreement by Q4 2013, and complete the new partnership
before the end of 2013. The Full Research Report on Health Management
Associates Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/96e5_HMA]

--

IDEXX Laboratories, Inc. Research Report

On June 13, 2013, IDEXX Laboratories, Inc. (IDEXX) announced that it is
partnering with laboratories worldwide to offer confirmatory pregnancy testing
using milk samples with the new IDEXX Milk Pregnancy Test. With this test,
dairy farmers can get early, accurate identification of open cows by simply
requesting the IDEXX Milk Pregnancy Test for samples they already submitted
for milk-quality testing, or by sending samples directly to participating
laboratories. According to the Company, the IDEXX Milk Pregnancy Test uses
trusted ELISA technology to detect pregnancy-associated glycoproteins (PAGs)
and determine pregnancy. It can provide accurate information as early as 35
days post breeding and also provides accuracy similar to that of palpation and
ultrasound, while also minimizing animal handling. The Full Research Report on
IDEXX Laboratories, Inc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/b565_IDXX]

--

ISIS Pharmaceuticals Inc. Research Report

On June 10, 2013, Isis Pharmaceuticals Inc. (Isis) and Xenon Pharmaceuticals
Inc. (Xenon) announced that Xenon has exercised its option to an exclusive
worldwide license to XEN701, an antisense drug that was discovered as a result
of collaboration between the two companies. Xenon plans to initially develop
XEN701 for patients with chronic kidney disease who are intolerant of or who
are poor responders to erythropoietin (Epo) therapy. B. Lynne Parshall, Chief
Operating Officer at Isis, said, "By working with partners like Xenon, who are
highly innovative and dedicated to a therapeutic area, we are able to expand
the breadth of our antisense drug pipeline while staying focused on our
internal drug discovery and development activities." Subsequent to this step,
Isis earns a $2 million payment from Xenon for the license of XEN701. The Full
Research Report on ISIS Pharmaceuticals Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.wsreports.com/r/full_research_report/f5f5_ISIS]

--

Trius Therapeutics Inc. Research Report

On June 12, 2013, Trius Therapeutics Inc. (Trius Therapeutics) announced the
publication of the results from multiple clinical and animal studies showing
that the Company's experimental antibiotic, tedizolid phosphate (TR-701), does
not interact with monamine oxidase (MAO). The results were published in the
July 2013 (Volume 57 Number 7) print issue of Antimicrobial Agents and
Chemotherapy. According to Trius Therapeutics, the findings suggest that, if
approved, tedizolid could potentially be taken with commonly prescribed
medicines such as many antidepressants, whose use is limited with agents that
inhibit MAO. The Company will include these results in its new drug
application (NDA) for tedizolid for the treatment of acute bacterial skin and
skin structure infections (ABSSSI), which it plans to file in the second half
of 2013. The Full Research Report on Trius Therapeutics Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.wsreports.com/r/full_research_report/1eb9_TSRX]

----

EDITOR NOTES:

 1. This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
 2. Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
 3. This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
 4. If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
 5. For any urgent concerns or inquires, please contact us at
    compliance@EquityNewsNetwork.com.
 6. Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Wall Street Reports

Contact: WSReports.com Phone #: +1-310-496-8071 (North America)
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement